Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb clinical trial for IFX-1 in hidradenitis suppurativa (HS) patients

Trial Profile

A Phase IIb clinical trial for IFX-1 in hidradenitis suppurativa (HS) patients

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs IFX 1 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2018 According to InflaRx media release, study will be conducted in approximately 20 sites in the U.S.
    • 28 Jun 2018 According to InflaRx media release, company announced the approval of their Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The open IND will allow InflaRx to start this study.
    • 15 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top